Making a New, Big Splash in the Sequencing Market

If one of the first ingredients of a successful tool company deal is to invest as little capital as possible, what then to make of the hefty $27 million raised by Helicos, a developer of high-throughput sequencing systems? The company that successfully integrates the technologies needed for single-molecule sequencing could find a fast and rewarding exit, and neither their investors nor management reject the possibility of a buy-out even before their products hit the market in a few years.

If, as monthly START-UP contributor Michael Lytton (general partner at Oxford Bioscience Partners) wrote in a recent "Nothing Ventured" column, "the first ingredient of a successful tool company deal is to invest as little capital as possible" (see "The Value in Tool Companies," START-UP, March 2004 Also see "The Value in Tool Companies" - Scrip, 1 March, 2004.), what then to make of the hefty $27 million raised by Helicos BioSciences Corp. , a developer of high-throughput sequencing systems, in its initial venture round in February? [See Deal] Only one other privately held tool company has raised more than $20 million since last September—ParAllele BioScience Inc. , also a developer of high-throughput genomics tools, in its B round last fall. [See Deal](See "ParAllele BioScience Inc.," START-UP, October 2003 Also see "ParAllele BioScience Inc." - Scrip, 1 October, 2003..)

Along with the usual arguments--the pedigree of its founders and advisers (which in Helicos' case include Leroy Hood, PhD, the inventor of the first automated DNA sequencer, and genomics pioneer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By 

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By 

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By 

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By 

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Business

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By 

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

 
• By 

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

 
• By 

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.